Open an account

Decoy Therapeutics

DCOY · NASDAQ

$1.14−$0.035 (−2.99%)TodayMarket closed ·
Prev close $1.17

About DCOY

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

Employees
11
Headquarters
Houston, Texas
Listed
Jan 29, 2015
Sector
Health Care
Industry
Biotechnology
Website
salariuspharma.com

DCOY key statistics

Market cap
2.71M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.80M
Volume
32.68K
Open price
$1.17
High today
$1.17
Low today
$1.11
52 Week high
$50.60
52 Week low
$1.15

Decoy Therapeutics (DCOY) at a glance

Decoy Therapeutics (DCOY) last traded at $1.14, with a market cap of 2.71M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.11 and $1.17. The current price is 1.9% above the day's low and 3.0% below its high.

Volume so far is 32.68K shares, below the average of 6.80M shares a day.

Over the past year Decoy Therapeutics has ranged from $1.15 to $50.60, and now sits 0% of the way up that range.

Decoy Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY24 it reported -$136.80 per share against an estimate of -$440.64.

The average analyst price target is $3.06, 169.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $3.06
Low
$3.03
Now
$1.14
High
$3.15

DCOY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 40.6% on average.

  1. Q2 FY22: reported -$3,240.00 per share against an estimate of -$3,855.60
  2. Q3 FY22: reported -$3,556.80 per share against an estimate of -$3,745.44
  3. Q4 FY22: reported -$4,075.20 per share against an estimate of -$3,165.26
  4. Q1 FY23: reported -$3,211.20 per share against an estimate of -$3,672.00
  5. Q2 FY23: reported -$2,059.20 per share against an estimate of -$1,904.55
  6. Q3 FY23: reported -$936.00 per share against an estimate of -$1,762.56
  7. Q1 FY24: reported -$590.40 per share against an estimate of -$9,840.96
  8. Q3 FY24: reported -$136.80 per share against an estimate of -$440.64

DCOY news

  • Press releasePRNewswire

    Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program

  • Press releasePRNewswire

    Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

  • Avi Kapoor

    Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results

  • Press releasePRNewswire

    Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

  • Press releaseGlobe Newswire

    Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

  • Avi Kapoor

    Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings

  • Press releasePRNewswire

    Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding

  • Press releasePRNewswire

    /C O R R E C T I O N -- Decoy Therapeutics, Inc/

Similar companies

Companies in the same industry as Decoy Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.